ScholarIQanswers from OpenAlex
Casma Therapeutics (United States)
InstitutionResearch output, impact & collaborations
Casma Therapeutics (United States) is a institution indexed in ScholarIQ from OpenAlex.
What is known about Casma Therapeutics (United States)?
ScholarIQrecord summary
Casma Therapeutics (United States) is a research organisation in Cambridge, United States. OpenAlex records 45 works and 3,818 citations for it. 2 researchers list it as their most recent affiliation.
How many works does Casma Therapeutics (United States) have?
ScholarIQindexed works
Casma Therapeutics (United States) has 45 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Casma Therapeutics (United States) have?
ScholarIQcitation count
Casma Therapeutics (United States) has 3,818 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Casma Therapeutics (United States)?
ScholarIQresearcher count
Casma Therapeutics (United States) has 2 researchers in the ScholarIQ index.
What is the average h-index at Casma Therapeutics (United States)?
ScholarIQavg h-index
Casma Therapeutics (United States) has an average h-index of 55 in OpenAlex.
What is the ROR of Casma Therapeutics (United States)?
ScholarIQror
The ROR for Casma Therapeutics (United States) is on the source record.
What is the OpenAlex record for Casma Therapeutics (United States)?
ScholarIQopenalex
The OpenAlex for Casma Therapeutics (United States) is on the source record.
Who are the most-cited researchers behind Casma Therapeutics (United States)?
ScholarIQtop researchers by citations
What are the most-cited papers on Casma Therapeutics (United States)?
ScholarIQmost cited works
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Marcin Imieliński, Alice H. Berger, Peter S. Hammerman, Bryan Hernandez, Trevor J. Pugh, Eran Hodis, Jeonghee Cho, James Suh, Marzia Capelletti, Andrey Sivachenko, Carrie Sougnez, Daniel Auclair, Michael S. Lawrence, Petar Stojanov, Kristian Cibulskis, Kyusam Choi, Luc de Waal, Tanaz Sharifnia, Angela N. Brooks, Heidi Greulich, Shantanu Banerji, Thomas Zander, Danila Seidel, Frauke Leenders, Sascha Ansén, Corinna Ludwig, Walburga Engel-Riedel, Erich Stoelben, Jürgen Wolf, Chandra Goparju, Kristin Thompson, Wendy Winckler, David J. Kwiatkowski, Bruce E. Johnson, Pasi A. Jänne, Vincent A. Miller, William Pao, William D. Travis, Harvey I. Pass, Stacey Gabriel, Eric S. Lander, Roman K. Thomas, Levi A. Garraway, Gad Getz, Matthew Meyerson
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama, Esra A. Akbay, Yvonne Y. Li, Grit S. Herter-Sprie, Kevin A. Buczkowski, William G. Richards, Leena Gandhi, Amanda J. Redig, Scott J. Rodig, Hajime Asahina, Robert E. Jones, Meghana Kulkarni, Mari Kuraguchi, Sangeetha Palakurthi, Peter E. Fecci, Bruce E. Johnson, Pasi A. Jänne, Jeffrey A. Engelman, Sidharta P. Gangadharan, Daniel B. Costa, Gordon J. Freeman, Raphael Bueno, F. Stephen Hodi, Glenn Dranoff, Kwok‐Kin Wong, Peter S. Hammerman
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Esra A. Akbay, Shohei Koyama, Julián Carretero, Abigail Altabef, Jeremy H. Tchaicha, Camilla L. Christensen, Oliver R. Mikse, Andrew D. Cherniack, Ellen M. Beauchamp, Trevor J. Pugh, Matthew D. Wilkerson, Peter E. Fecci, Mohit Butaney, Jacob B. Reibel, Margaret Soucheray, Travis J. Cohoon, Pasi A. Jänne, Matthew Meyerson, D. Neil Hayes, Geoffrey I. Shapiro, Takeshi Shimamura, Lynette M. Sholl, Scott J. Rodig, Gordon J. Freeman, Peter S. Hammerman, Glenn Dranoff, Kwok‐Kin Wong
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Diana Miao, Claire A. Margolis, Natalie I. Vokes, David Liu, Amaro Taylor‐Weiner, Stephanie A. Wankowicz, Dennis O. Adeegbe, Daniel Keliher, Bastian Schilling, Adam Tracy, Michael P. Manos, Nicole G. Chau, Glenn J. Hanna, Paz Polak, Scott J. Rodig, Sabina Signoretti, Lynette M. Sholl, Jeffrey A. Engelman, Gad Getz, Pasi A. Jänne, Robert I. Haddad, Toni K. Choueiri, David A. Barbie, Rizwan Haq, Mark M. Awad, Dirk Schadendorf, F. Stephen Hodi, Joaquim Bellmunt, Kwok‐Kin Wong, Peter S. Hammerman, Eliezer M. Van Allen
<i>MET</i> Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent <i>MET</i> Genomic Amplification and c-Met Overexpression
Mark M. Awad, Geoffrey R. Oxnard, David M. Jackman, Daniel O. Savukoski, Dimity Hall, Priyanka Shivdasani, Jennifer Heng, Suzanne E. Dahlberg, Pasi A. Jänne, Suman Verma, James G. Christensen, Peter S. Hammerman, Lynette M. Sholl
How much of the research on Casma Therapeutics (United States) is open access?
ScholarIQopen access share
89%OPEN ACCESS